Hernán Trimarchi - Concepedia

Author

Hernán Trimarchi

Hospital Británico de Buenos Aires ORCID

Also Known As

H M Trimarchi, H Trimarchi, H. Trimarchi, Herman Trimarchi, Hernan M. Trimarchi, Hernan TRIMARCHI, Hernan Trimarchi, Hernán M Trimarchi, Hernán M. Trimarchi, Hernán Trimarchi

215

Publications

5.3K

Citations

H-Index

Concepts

All Affiliations

Hospital Británico de Buenos Aires University of Leicester Peking University Peking University First Hospital The Ohio State University Wexner Medical Center

About

Hernán Trimarchi is an author at Hospital Británico de Buenos Aires specializing in medicine, nephrology, and chronic kidney disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	18	938
2	Public Health	3	3	78
3	Diabetes	2	2	47
4	Language Studies	1	1	15
5	Blood Transplantation	1	1	27

Hernán Trimarchi

Publications

2.9K

Citations

H-Index

Page 1

	Year	Citations
A Multicenter Study of the Predictive Value of Crescents in IgA Nephropathy Mark Haas, Jacobien C. Verhave, Zhihong Liu, Journal of the American Society of Nephrology	2016	299
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial Richard Lafayette, Jens Kristensen, Andrew Stone, The Lancet Primary Iga NephropathyGlomerulonephritisRenal FunctionMedicineRandomised Phase 3	2023	234
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink, The Lancet	2023	224
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy Jonathan Barratt, Richard Lafayette, Jens Kristensen, Kidney International	2022	205
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers, The Lancet GlomerulonephritisActive-controlled Clinical TrialRenal FunctionKidney FailureChronic Kidney Disease	2023	203
Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy Krzysztof Kiryluk, Elena Sánchez, Francesca Zanoni, Nature Genetics Genome-wide Association StudyGlomerulonephritisGenome-wide AssociationAutoimmune DiseaseMedicine	2023	156
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy Vlado Perkovic, Jonathan Barratt, Brad H. Rovin, New England Journal of Medicine	2024	117
Nationwide and Long-Term Survey of Primary Glomerulonephritis in Japan as Observed in 1,850 Biopsied Cases M. Brack, Carsten Schroeder, Margrit Fooke, The Nephron journals/Nephron journals	1999	114
Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy Hong Zhang, Dana V. Rizk, Vlado Perkovic, Kidney International	2023	109
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis Michelle N. Rheault, Charles E. Alpers, Jonathan Barratt, New England Journal of Medicine	2023	94

Page 1